European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
March 15, 2019 02:00 ET
|
F. Hoffmann-La Roche Ltd
MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the...
European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
March 14, 2019 02:00 ET
|
F. Hoffmann-La Roche Ltd
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison Only prophylactic medicine that can be given...
Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
March 11, 2019 02:03 ET
|
F. Hoffmann-La Roche Ltd
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are...
Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
March 11, 2019 02:03 ET
|
F. Hoffmann-La Roche Ltd
PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about 300,000 women are...
FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
March 11, 2019 02:00 ET
|
F. Hoffmann-La Roche Ltd
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Basel, 11...
FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
March 11, 2019 02:00 ET
|
F. Hoffmann-La Roche Ltd
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need Basel, 11...
European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
March 08, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer...
European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
March 08, 2019 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer...
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
March 07, 2019 11:35 ET
|
F. Hoffmann-La Roche Ltd
Basel, 7 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc....
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
March 07, 2019 11:35 ET
|
F. Hoffmann-La Roche Ltd
Basel, 7 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc....